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doi:10.1016/j.kjms.2011.11.012Abstract Transforming growth factor (TGF) b1 may be a candidate for a serologic tumor
marker. In this study, the plasma levels of TGF-b1 in patients with brain tumors were measured
using enzyme-linked immunosorbent assay before and after tumor removal. Patients were
divided into four groups, the control group and the benign, malignant, and metastatic brain
tumor groups. All brain tumor groups showed significant increases in the levels of TGF-b1
before tumor removal (6.36  3.94, 17.0  9.7, and 12.2  10.3 ng/ml for the benign, malig-
nant, and metastatic groups, respectively). When compared with the results obtained in the
control group (1.12  0.74 ng/ml), significant decreases in TGF-b1 concentrations after total
tumor removal were found in both the benign and malignant brain tumor groups
(2.55  2.00 and 8.93  5.73 ng/ml, respectively; p Z 0.0001 and p Z 0.003, respectively).
On the other hand, plasma TGF-b1 levels in the metastatic brain tumor group showed a slight
but significant increase (14.7  9.3 ng/ml, p Z 0.035) after tumor removal. In a case of low-
grade astrocytoma, plasma levels of TGF-b1 were found to be 3.6 and 1.1 ng/ml before and
after tumor removal, respectively. However, recurrent tumor was noted in this patient
7 months later, and the levels of TGF-b1 were 26.2 and 8.4 ng/ml before and after the secondHwa Road, Yung Kang City, Tainan, Taiwan.
t.net (C.-C. Chio).
vier Taiwan LLC. All rights reserved.
TGF-b1 levels in brain tumors 317operation, respectively. The data show that plasma TGF-b1 was elevated in the circulation of
patients with brain tumors and that significant decreases in TGF-b1 levels were observed after
the removal of benign and malignant tumors. The results also suggest that TGF-b1 may be
a useful serologic marker for brain tumors.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Table 1 The plasma levels of transforming growth factor
b1 before and after tumor removal in benign brain tumor.
Case
No
Sex Age
(yr)
Diagnosis ng/ml
Preop Postop
1 Woman 57 Meningioma 5.5 4.8Introduction
Transforming growth factor beta (TGF-b) is a family of
multifunctional cytokines that regulate cell proliferation,
differentiation, and extracellular matrix production [1,2].
Deregulation of the expression or signaling of TGF-b has
been implicated in the pathogenesis of a variety of
diseases, including cancer [3] and fibrosis [4]. Under phys-
iologic conditions, TGF-b inhibits the proliferation of
normal astrocytes but it loses its growth-inhibitory poten-
tial toward gliomas due to alterations in the expression of
cell cycle inhibitors. Lines of evidence suggest that TGF-b is
actively secreted by tumor cells in the late stages of cancer
development, and it contributes to cell growth, invasion,
metastasis as well as to the decrease in host-tumor immune
responses [1]. There are three distinct TGF-b isoforms
(namely, TGF-b1, TGF-b2, and TGF-b3) and their effects
depend on the type, differentiation state, and physiologic
conditions of the target cells [3]. Among the TGF-b iso-
forms, TGF-b1 is the most abundant and most universally
expressed compared with the other two [4,5]. Because of
these properties, TGF-b1 has been the focus of most of the
preclinical and clinical studies.
A recent report demonstrated that elevated serum level
of TGF-b1 was a more sensitive indicator of small hepato-
cellular carcinomas than alpha-fetoprotein, which suggests
that measuring serum TGF-b1 levels may be clinically useful
for the diagnosis of others tumors as well [6]. Furthermore,
based on preclinical studies that showed the production of
TGF-b1 by tumors, we hypothesized that the TGF-b1 level
should decrease after the surgical removal of the tumors.
Thus, we compared the plasma levels of TGF-b1 in patients
with brain tumors before and after tumor removal and
evaluated the potential of using this measurement as a new
tool for the diagnosis and monitoring of malignancy in brain
tumors.2 Woman 59 Meningioma 8.2 5.1
3 Man 66 Meningioma 4.9 2.8
4 Woman 44 Meningioma 6.2 2.1
5 Woman 79 Meningioma 6.1 3.6
6 Woman 48 Meningioma 3.4 0.5
7 Woman 63 Meningioma 6.1 1.6
8 Woman 10 Low-grade astrocytoma 3.6 1.1
9 Man 55 Low-grade astrocytoma 0.8 0.3
10 Man 52 Neurilemmoma 1.9 0.4
11 Woman 70 Meningioma 12.3 7.5
12 Man 24 Meningioma 9.6 3.3
13 Man 58 Meningioma 4.7 1.3
14 Woman 64 Meningioma 4.2 1.9
15 Woman 43 Pituitary adenoma 11.6 2.8
16 Woman 44 Meningioma 15.6 3.7
17 Woman 48 Meningioma 3.4 0.5Patients and methods
The study protocol was approved by the ethics review
committee of the Medical Faculty of the Kaohsiung Medical
University Hospital in Kaohsiung, Taiwan. All patients and
controls gave their written informed consent. From
September 2004 to December 2006, 68 patients were
included in this study. Among them, 17 had benign brain
tumors (13 with meningiomas, two with low-grade astro-
cytoma, and one each with pituitary adenoma and neu-
rilemmoma), 14 had malignant brain tumors (six with
glioblastoma multiforme, three each with anaplastic
astrocytoma and malignant meningioma, and two with
gliosarcoma), 24 had metastatic brain tumors (15 with lungcarcinomas, three with melanoma, and one each with
breast carcinoma, colon carcinoma, hepatoma, cervical
carcinoma, neuroblastoma, and malignant thymoma) and
13 were controls (all received cranioplasty for skull bone
defect). Blood samples (10 ml) were collected in tubes
containing 10 mg of ethylenediaminetetraacetic acid and
0.15 ml of aprotinin from patients before and 7 days after
surgery. The samples were centrifuged at 2000  g for
10 minutes, and the supernatants were carefully aspirated
and stored at e20C until analysis. The plasma TGF-b1 level
was measured with enzyme-linked immunosorbent assay
(ELISA) kits (Biosource International, Carlsbad, California
USA) of antibody sandwich format as described previously
[7]. The first antibody used to coat the plates (capture
antibody) is a monoclonal antibody 4A11, which was used as
the detection antibody. Streptavidin-conjugated horse-
radish peroxidase (HRP) was used as the secondary anti-
body; H2O2 mixed with tetramethylbenzidine was the
substrate. The 96-well microtiter plates were applied to an
automatic plate reader to measure the absorbance at
450 nm using 540 nm as a wavelength correction. The
TGF-b1 level was assayed by comparing the peroxidase
activity in wells containing known amounts of purified
TGF-b1 with the activity in the wells containing the plasma
of the patient. The known amounts of purified TGF-b1 were
used as a standard for ELISA. Samples were run in triplicate.
Each assay was repeated to ensure the absorbance values
Table 2 The plasma levels of transforming growth factor
b1 before and after tumor removal in malignant brain
tumor.
Case
No
Sex Age
(yr)
Diagnosis ng/ml
Preop Postop
1 Man 73 Gr III astrocytoma 7.5 4.0
2 Woman 57 Glioblastoma multiforme 24.9 9.1
3 Woman 70 Glioblastoma multiforme 6.5 5.3
4 Man 26 Gliosarcoma 27.0 8.6
5 Woman 52 Glioblastoma multiforme 10.8 6.5
6 Man 78 Glioblastoma multiforme 7.1 3.2
7 Man 51 Gliosarcoma 7.3 11.7
8 Woman 10 Glioblastoma multiforme 26.2 8.4
9 Woman 43 Malignant meningioma 11.0 2.8
10 Woman 65 Gr III astrocytoma 25.8 15.4
11 Woman 50 Malignant meningioma 29.2 15.2
12 Woman 42 Glioblastoma multiforme 7.0 1.0
13 Woman 75 Malignant meningioma 30.2 20.5
14 Man 42 Gr III astrocytoma 18.0 13.0
Table 4 Plasma levels of transforming growth factor b1
(TGF-b1) before and after tumor removal.
Group TGF-b1 (ng/ml) p
valuePreoperation
(mean  SEM)
Postoperation
(mean  SEM)
Control (n Z 13) 1.12  0.74 1.43  0.85 0.183
Benign (n Z 17) 6.36  3.94 2.55  2.0 0.0001
Malignant (n Z 14) 17.0  9.7 8.93  5.73 0.003
Metastatic (n Z 24) 12.2  10.3 14.7  9.3 0.035
Statistical significance was conducted by Wilcoxon signed rank
test (p < 0.05).
318 J.-K. Loh et al.were within the range of the detectable standard cure.
Since the procedure could not distinguish between the
active and latent forms of TGFb1, the measured TGFb1
level was referred to as the total TGFb1.
Comparison between various groups was conducted
using Wilcoxon signed rank test, and a p value of less than
0.05 was considered to be statistically significant.Table 3 The plasma levels of transforming growth factor b1 be
Case No Sex Age (yr)
1 Woman 65 Lung c
2 Man 78 Lung c
3 Woman 10 Neurob
4 Woman 52 Melano
5 Man 81 Melano
6 Woman 77 Melano
7 Woman 68 Lung c
8 Woman 54 Breast
9 Man 54 Lung c
10 Woman 74 Lung c
11 Woman 65 Lung c
12 Woman 65 Lung c
13 Woman 71 Lung c
14 Man 77 Lung c
15 Man 72 Lung c
16 Woman 55 Cervica
17 Man 70 Lung c
18 Man 54 Lung c
19 Man 65 Lung c
20 Man 67 Thymo
21 Man 66 Lung c
22 Man 65 Colon c
23 Man 44 Hepato
24 Man 75 Lung cResults
The clinical data and plasma levels of TGF-b1 of benign
brain tumor, malignant brain tumor, and metastatic brain
tumor are shown in Tables 1 to 3 respectively.
The plasma levels of TGF-b1 in patients before and after
tumor removal are shown in Table 4. Prior to surgery,
plasma TGF-b1 levels in the benign (6.36  3.94 ng/ml,
mean  SEM), malignant (17.0  9.7 ng/ml), and metastatic
(12.2  10.3 ng/ml) brain tumor groups were significantly
higher than the control (1.1  0.7 ng/ml). Significant
decreases in TGF-b1 levels were found in benign
(2.55  2.00 ng/ml; p Z 0.0001) and malignant
(8.93  5.73 ng/ml; p Z 0.003) brain tumor groups after
tumor removal. However, a slight but significant increase infore and after tumor removal in metastatic brain tumor.
Diagnosis ng/ml
Preop Postop
ancer with brain meta 4.1 4.1
ancer with brain meta 1.7 1.6
lastoma with brain meta 4.2 2.8
ma with brain meta 1.5 3.3
ma with brain meta 2.1 3.7
ma with brain meta 9.1 8.5
ancer with brain meta 19.3 26.9
cancer with brain meta 7.9 14.6
ancer with brain meta 17.9 26.8
ancer with brain meta 18.7 30.6
ancer with brain meta 13.9 20.2
ancer with brain meta 15.0 21.9
ancer with brain meta 26.3 25.0
ancer with brain meta 29.3 23.4
ancer with brain meta 29.7 21.8
l cancer with brain meta 25.1 18.8
ancer with brain meta 29.0 23.3
ancer with brain meta 18.7 21.6
ancer with brain meta 10.4 15.2
ma with brain meta 1.7 5.7
ancer with brain meta 0.8 10.6
ancer with brain meta 4.6 12.8
ma with brain meta 1.5 5.9
ancer with brain meta 0.5 4.0
TGF-b1 levels in brain tumors 319plasma TGF-b1 levels was seen in the metastatic brain
tumor group (14.7  9.3 ng/ml; p Z 0.035) after surgery
(Table 4).
Brain magnetic resonance images of a case of low-grade
astrocytoma are shown in Fig. 1 (top panel). Grossly, total
removal of this low-grade astrocytoma was performed in
this patient (Figs. 1A and 1B, top panel). Plasma TGF-b1
levels of this patient before and after tumor removal were
3.6 and 1.1 ng/ml, respectively (Fig. 1, bottom panel). The
patient had a recurrent tumor 7 months later (Fig. 1C, top
panel). A second operation was performed (Fig. 1D; topFigure 1. Brain magnetic resonance images (MRI) and plasma TG
after tumor removal. Top panel: MRI of the right temporo-pariental
performed. Tumor recurred seven months later in this patient, and
Bottom panel: corresponding plasma TGF-b1 levels for the same ppanel), and the pathologic report revealed glioblastoma
multiforme. The TGF-b1 concentrations of this patient
before and after the second surgery were 26.2 and 8.4 ng/
ml, respectively (Fig. 1; bottom panel).Discussion
Malignant tumors secrete into the circulation a number of
proteins and peptides such as human chorionic gonado-
tropin, carcinoembryonic antigen, and alpha-fetoprotein,F-b1 levels of a patient with Grade II astrocytoma before and
lobe before (A) and after (B) a grossly total tumor removal was
images were taken before (C) and after (D) a second operation.
atient.
320 J.-K. Loh et al.which can be used as helpful markers for the diagnosis,
therapy, and prognosis of cancers. Likewise, TGF-b1 has
recently emerged as such a marker for brain tumors [8e10].
In the present study, we measured plasma TGF-b1 levels
in patients with brain tumors before and after tumor
removal. Our data showed that the plasma TGF-b1 levels in
patients with brain tumor before surgical management
were significantly higher than those of healthy controls,
suggesting that TGF-b1 was indeed produced by brain
tumors. Furthermore, significant decreases in plasma TGF-
b1 were found after tumor removal in both the benign and
malignant brain tumor groups. These results are consistent
with our hypothesis that surgical removal of the brain
tumors can reduce the production of TGF-b1.
On the other hand, there was a slight but significant
increase in plasma TGF-b1 levels in patients with meta-
static brain tumor despite a significant tumor reduction by
surgery. The results indicate that a quantity of unknown
tumor cell clones may still reside outside the circumscribed
tumor that has been removed surgically. These residual
tumors together with another main tumor that were not
removed were likely to be responsible for the production of
TGF-b1 after surgery. Such an increase in TGF-b1 levels in
the metastatic brain tumor group may also reflect the less
favorable outcome in these patients.
In a murine malignant glioma model, high-grade human
brain tumors have been shown to produce higher levels of
TGF-b1 than those from low-grade brain tumors and from
normal brain tissue [11e14]. When different histologic
subgroups of gliomas were examined, TGF-b1 production
was found to increase with anaplastic grade [15]. Further-
more, TGF-b1 production was significantly higher in glio-
blastomas than in the slow-growing glioma. In the present
study we have also shown that plasma TGF-b1 levels in
patients with malignant tumors are significantly higher than
those with benign tumors before tumor removal (Table 4).
The results imply that the malignant brain tumors synthe-
size higher amounts of TGF-b1 than benign tumors.
Consequently, malignant brain tumors can induce more
severe immunosuppression, and immunosuppression in
a tumor-bearing host is a major obstacle in cancer treat-
ment. TGF-b1 can down-regulate monocyte surface marker
expression, cytokine secretion, cytotoxicity, and T-cell
responsiveness, all of which paralyze the immune system of
the host, thus contributing to the growth and progression of
tumors [16e21].
In addition, immunosuppression may also lead to the
development of tumor metastases in cancer patients. It has
been widely accepted that the tumor-induced immuno-
suppression is associated with tumor burden. However, an
important question remains as to whether immunosup-
pression could be reversed if the tumor burden is lessened.
Previous studies have revealed that antitumor immune
function could recover partially following reduction of
tumor burden via primary tumor resection [22e25]. In other
words, tumor-induced immunosuppression could be
partially reversed by tumor resection in cancer patients.
Our results reveal that the plasma levels of TGF-b1
decrease after brain tumor removal, which may lead to the
possible lessening or relieving of host immune suppression.
In conclusion, the present study showed that plasma
TGF-b1 levels in the benign and malignant brain tumorgroups were elevated and that surgical removal of the
tumors reduced the production of this cytokine. These
results suggest that plasma TGF-b1 may be used as a marker
for the diagnosis and monitoring of tumor malignancy.
Further investigations are warranted to determine whether
these findings contribute to morbidity and mortality or
therapeutic outcome.References
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